- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo, TCS Cream
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 3,153
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
- Interventions
- Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 124
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
- Conditions
- Ulcerative Colitis
- Interventions
- OPC-6535, Asacol®
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Los Angeles, California • Hollywood, Florida + 23 more
- Conditions
- Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
- Interventions
- Ritlecitinib, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 607 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Encinitas, California • Huntington Beach, California + 31 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Interventions
- Inhaled Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
- Conditions
- HR+ HER2- Breast Cancer
- Interventions
- Serabelisib, Sapanisertib, Fulvestrant
- Drug
- Lead sponsor
- Faeth Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more
- Conditions
- Keratitis, Corneal Ulcer
- Interventions
- PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears
- Combination Product · Other
- Lead sponsor
- Peschke GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
- Conditions
- COVID-19
- Interventions
- Shionogi Protease Inhibitor (S-217622), placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, recombinant interferon alfa, dexamethasone, melphalan, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Up to 69 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Sarcoma
- Interventions
- filgrastim, doxorubicin hydrochloride, ifosfamide, mesna, vincristine sulfate, conventional surgery, brachytherapy, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 7
- States / cities
- Wichita, Kansas • New Orleans, Louisiana • Memphis, Tennessee + 4 more
- Conditions
- Advanced Solid Tumor, Breast Cancer
- Interventions
- CFI-402257, Fulvestrant
- Drug
- Lead sponsor
- Treadwell Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Columbus, Ohio • San Antonio, Texas • West Valley City, Utah + 1 more
- Conditions
- Neuroblastoma
- Interventions
- carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 12 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2021
- U.S. locations
- 166
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more
- Conditions
- Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
- Interventions
- Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
- Drug · Radiation · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2037
- U.S. locations
- 679
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin
- Biological · Procedure · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus
- Interventions
- Beta-hydroxy-butyrate
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Lung Diseases, Interstitial
- Interventions
- BI 1015550, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
- Conditions
- Advanced Solid Tumors
- Interventions
- VVD-159642, Sotorasib, Trametinib
- Drug
- Lead sponsor
- Vividion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Grand Rapids, Michigan • Austin, Texas • Irving, Texas + 3 more
- Conditions
- Acute Leukemia
- Interventions
- Bleximenib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 26
- States / cities
- Duarte, California • Orange, California • San Francisco, California + 20 more
- Conditions
- Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Interventions
- Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 50 more
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
- Biological
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 55 Days to 89 Days
- Enrollment
- 7,744 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
- Conditions
- Ulcerative Colitis
- Interventions
- Filgotinib, PTM filgotinib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 61
- States / cities
- Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Efavaleukin Alfa, Placebo, Standard of Care
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 40 more
- Conditions
- Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 71 more